LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Back to previous search Search history
Advanced search

Your last searches

  1. AU="Sexton, Marybeth"
  2. AU="Coutinho, Guilherme"

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Perioperative use of cefazolin without preliminary skin testing in patients with reported penicillin allergy.

    Kuruvilla, Merin / Wolf, Francis / Sexton, Marybeth / Wiley, Zanthia / Thomas, Jamie

    Surgery

    2018  Volume 165, Issue 2, Page(s) 486–496

    MeSH term(s) Antibiotic Prophylaxis ; Cefazolin ; Drug Hypersensitivity ; Humans ; Penicillins ; beta-Lactams
    Chemical Substances Penicillins ; beta-Lactams ; Cefazolin (IHS69L0Y4T)
    Language English
    Publishing date 2018-07-10
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 202467-6
    ISSN 1532-7361 ; 0039-6060
    ISSN (online) 1532-7361
    ISSN 0039-6060
    DOI 10.1016/j.surg.2018.05.054
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uk I Zs.129: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: A Streamlined Approach to Optimize Perioperative Antibiotic Prophylaxis in the Setting of Penicillin Allergy Labels.

    Kuruvilla, Merin / Sexton, Marybeth / Wiley, Zanthia / Langfitt, Terry / Lynde, Grant C / Wolf, Francis

    The journal of allergy and clinical immunology. In practice

    2019  Volume 8, Issue 4, Page(s) 1316–1322

    Abstract: Background: Patients with penicillin allergy labels often receive alternative antibiotics for perioperative prophylaxis, as opposed to first-line cephalosporins (cefazolin/cefuroxime). Provider misconceptions about the risk of cross-reactivity likely ... ...

    Abstract Background: Patients with penicillin allergy labels often receive alternative antibiotics for perioperative prophylaxis, as opposed to first-line cephalosporins (cefazolin/cefuroxime). Provider misconceptions about the risk of cross-reactivity likely drive this prescribing behavior, which is problematic because of its association with increased risk of surgical-site infections.
    Objective: To develop, implement, and assess the safety of a streamlined approach to perioperative antibiotic selection for surgical patients with a penicillin allergy label, to reduce the use of second-line antibiotics.
    Methods: A multidisciplinary task force developed an institutional algorithm for antibiotic selection in penicillin-allergic surgical patients. The percentage of patients receiving a first-line cephalosporin was compared before and after algorithm utilization. The safety of this approach was assessed via chart review of all patients who received epinephrine or diphenhydramine in the operating room, or diphenhydramine within 24 hours postoperatively, assessing for any adverse reactions to cephalosporin administration.
    Results: Between September 2016 and May 2019, 9.3% of surgical patients had documented penicillin allergy (n = 2296). At baseline, 22% of these patients received a cephalosporin, with an increase to more than 80% after algorithm implementation (P < .0001). Among 551 patients with penicillin allergy label who received a cephalosporin after algorithm implementation, no immediate allergic reactions requiring epinephrine were identified; 1 patient had a delayed rash that did not require cephalosporin discontinuation. Three patients received diphenhydramine for "itching" without rash in the setting of concomitant narcotic administration.
    Conclusions: Using a streamlined algorithm, we were able to significantly reduce the use of second-line antibiotics in penicillin-allergic surgical patients without severe adverse reactions.
    MeSH term(s) Anti-Bacterial Agents/adverse effects ; Antibiotic Prophylaxis ; Cephalosporins ; Drug Hypersensitivity/drug therapy ; Humans ; Penicillins/adverse effects
    Chemical Substances Anti-Bacterial Agents ; Cephalosporins ; Penicillins
    Language English
    Publishing date 2019-12-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2019.12.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7086: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Human Adenovirus 11 in 2 Renal Transplant Recipients: Suspected Donor-Derived Infection.

    Sherman, Amy C / Lu, Xiaoyan / Schneider, Eileen / Langston, Amelia / Ellis, Carla L / Pastan, Stephen / Bhatnagar, Julu / Reagan-Steiner, Sarah / Annambhotla, Pallavi / Lindstrom, Stephen / Mehta, Aneesh / Pouch, Stephanie M / Sexton, Marybeth E

    Open forum infectious diseases

    2021  Volume 8, Issue 3, Page(s) ofab092

    Abstract: Background: Human adenovirus (HAdV) infections can lead to high mortality in solid organ transplant (SOT) recipients, with rare reports of donor-derived infection.: Methods: Two renal transplant recipients with HAdV-11 infection who received kidneys ... ...

    Abstract Background: Human adenovirus (HAdV) infections can lead to high mortality in solid organ transplant (SOT) recipients, with rare reports of donor-derived infection.
    Methods: Two renal transplant recipients with HAdV-11 infection who received kidneys from the same donor are described. Whole-genome sequencing (WGS) was performed.
    Results: WGS showed 100% nucleotide sequence identity for the 2 HAdV-11 isolates. The patients presented with distinct clinical syndromes, and both were treated with brincidofovir.
    Conclusions: Donor-derived HAdV infection is presumed to be low; however, disseminated HAdV in SOT recipients can be severe, and clinicians should be aware of the clinical course and treatment options.
    Language English
    Publishing date 2021-02-25
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2757767-3
    ISSN 2328-8957
    ISSN 2328-8957
    DOI 10.1093/ofid/ofab092
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant.

    Edara, Venkata-Viswanadh / Manning, Kelly E / Ellis, Madison / Lai, Lilin / Moore, Kathryn M / Foster, Stephanie L / Floyd, Katharine / Davis-Gardner, Meredith E / Mantus, Grace / Nyhoff, Lindsay E / Bechnak, Sarah / Alaaeddine, Ghina / Naji, Amal / Samaha, Hady / Lee, Matthew / Bristow, Laurel / Hussaini, Laila / Ciric, Caroline Rose / Nguyen, Phuong-Vi /
    Gagne, Matthew / Roberts-Torres, Jesmine / Henry, Amy R / Godbole, Sucheta / Grakoui, Arash / Sexton, Marybeth / Piantadosi, Anne / Waggoner, Jesse J / Douek, Daniel C / Anderson, Evan J / Rouphael, Nadine / Wrammert, Jens / Suthar, Mehul S

    bioRxiv : the preprint server for biology

    2021  

    Abstract: The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the global emergence of SARS-CoV-2 variants with mutations in the spike ...

    Abstract The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the global emergence of SARS-CoV-2 variants with mutations in the spike protein, the principal antigenic target of these vaccines, has raised concerns over the neutralizing activity of vaccine-induced antibody responses. The Omicron variant, which emerged in November 2021, consists of over 30 mutations within the spike protein. Here, we used an authentic live virus neutralization assay to examine the neutralizing activity of the SARS-CoV-2 Omicron variant against mRNA vaccine-induced antibody responses. Following the 2nd dose, we observed a 30-fold reduction in neutralizing activity against the omicron variant. Through six months after the 2nd dose, none of the sera from naïve vaccinated subjects showed neutralizing activity against the Omicron variant. In contrast, recovered vaccinated individuals showed a 22-fold reduction with more than half of the subjects retaining neutralizing antibody responses. Following a booster shot (3rd dose), we observed a 14-fold reduction in neutralizing activity against the omicron variant and over 90% of boosted subjects showed neutralizing activity against the omicron variant. These findings show that a 3rd dose is required to provide robust neutralizing antibody responses against the Omicron variant.
    Language English
    Publishing date 2021-12-22
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2021.12.20.473557
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant

    Edara, Venkata-Viswanadh / Manning, Kelly E / Ellis, Madison / Lai, Lilin / Moore, Kathryn M / Foster, Stephanie L / Floyd, Katharine / Davis-Gardner, Meredith E / Mantus, Grace / Nyhoff, Lindsay E / Bechnack, Sarah / Alaaeddine, Ghina / Naji, Amal / Samaha, Hady / Lee, Matthew / Bristow, Laurel / Hussaini, Laila / Ciric, Caroline Rose / Nguyen, Phuong-Vi /
    Gagne, Matthew / Roberts-Torres, Jesmine / Henry, Amy R / Godbole, Sucheta / Grakoui, Arash / Sexton, Marybeth / Piantadosi, Anne / Waggoner, Jesse J / Douek, Daniel C / Anderson, Evan J / Rouphael, Nadine / Wrammert, Jens / Suthar, Mehul S

    bioRxiv

    Abstract: The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the global emergence of SARS-CoV-2 variants with mutations in the spike ...

    Abstract The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the global emergence of SARS-CoV-2 variants with mutations in the spike protein, the principal antigenic target of these vaccines, has raised concerns over the neutralizing activity of vaccine-induced antibody responses. The Omicron variant, which emerged in November 2021, consists of over 30 mutations within the spike protein. Here, we used an authentic live virus neutralization assay to examine the neutralizing activity of the SARS-CoV-2 Omicron variant against mRNA vaccine-induced antibody responses. Following the 2nd dose, we observed a 30-fold reduction in neutralizing activity against the omicron variant. Through six months after the 2nd dose, none of the sera from naive vaccinated subjects showed neutralizing activity against the Omicron variant. In contrast, recovered vaccinated individuals showed a 22-fold reduction with more than half of the subjects retaining neutralizing antibody responses. Following a booster shot (3rd dose), we observed a 14-fold reduction in neutralizing activity against the omicron variant and over 90% of boosted subjects showed neutralizing activity against the omicron variant. These findings show that a 3rd dose is required to provide robust neutralizing antibody responses against the Omicron variant.
    Keywords covid19
    Language English
    Publishing date 2021-12-22
    Publisher Cold Spring Harbor Laboratory
    Document type Article ; Online
    DOI 10.1101/2021.12.20.473557
    Database COVID19

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top